清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.

医学 实体瘤 癌症研究 内科学 肿瘤科 癌症
作者
Alexander I. Spira,James Y. Lau,Maureen M. Hattersley,Boaz E. Aronson,J.S. Peters,Yee Soo-Hoo,Aarti Sawant,Joanna I. Loizou,Claire Smith,Emma Dean,Sophie Postel‐Vinay,Benjamin Solomon
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (16_suppl): TPS3179-TPS3179 被引量:1
标识
DOI:10.1200/jco.2024.42.16_suppl.tps3179
摘要

TPS3179 Background: Protein arginine methyltransferase 5 (PRMT5) is an epigenetic enzyme that catalyzes symmetric dimethylation of arginine substrates, regulating multiple cell processes. Deletion of the methylthioadenosine phosphorylase gene MTAP in tumor cells results in accumulation of the metabolite methylthioadenosine (MTA), a partial inhibitor of PRMT5, potentially rendering tumor cells susceptible to further PRMT5 targeting. Clinical activity of first-generation, non-selective PRMT5 inhibitors (PRMT5i) is limited by bone marrow toxicity due to lack of selectivity between normal cells and MTAP-deficient tumor cells. Second-generation PRMT5i, including AZD3470, should selectively target MTAP-deficient tumor cells whilst sparing normal cells. AZD3470 preferentially binds PRMT5 in the presence of MTA in MTAP-deficient tumor cells, inhibiting PRMT5 methylation activity, and is less effective in MTAP-proficient cells. PRIMROSE (NCT06130553) is a first-in-human, Phase 1/2a, open-label, multicenter study of AZD3470 as monotherapy and in combination with anti-cancer agents in patients with MTAP-deficient advanced / metastatic solid tumors. Methods: Eligible patients are aged ≥18 years with MTAP-deficient advanced or refractory solid tumors, ≥1 prior line of treatment in the recurrent / metastatic setting, ≥1 measurable lesion per RECIST v1.1, ECOG performance status 0/1, adequate organ and bone marrow function, and no prior treatment with PRMT5i. Module 1 will evaluate AZD3470 monotherapy. Part A (dose escalation) will enroll up to ~54 patients and follow a modified toxicity probability interval-2 (mTPI-2) design with once-daily dosing in 21-day cycles. Treatment will be given until progression or discontinuation criteria are met. Part B (dose optimization and expansion) will expand specific patient populations and / or tumor types, with up to ~30 patients per cohort; dosing will be based on safety and tolerability data from Part A. Further modules for combination treatments may be added based on emerging supportive data. The primary objectives are to assess safety and tolerability, including dose-limiting toxicities, and to determine the recommended phase 2 dose of AZD3470. The secondary objective is evaluation of efficacy, including objective response rate, duration of response, disease control rate, change in tumor size, progression-free survival, and overall survival. An additional secondary objective in Module 1 is to assess pharmacokinetics. The study is planned to take place in ~20 centers across eight countries. The study was opened to enrollment in December 2023. Clinical trial information: NCT06130553 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Bennyz完成签到,获得积分10
5秒前
不空是空完成签到,获得积分0
9秒前
龙虾发票发布了新的文献求助20
40秒前
45秒前
宇文雨文完成签到 ,获得积分10
1分钟前
oaoalaa完成签到 ,获得积分10
1分钟前
marceloclaro发布了新的文献求助10
1分钟前
zilhua发布了新的文献求助30
1分钟前
wefor完成签到 ,获得积分10
1分钟前
wang完成签到,获得积分10
1分钟前
个性仙人掌完成签到 ,获得积分10
2分钟前
小白完成签到 ,获得积分10
2分钟前
CodeCraft应助DocRex采纳,获得10
2分钟前
zilhua完成签到,获得积分10
2分钟前
loulex完成签到,获得积分10
2分钟前
2分钟前
zilhua发布了新的文献求助10
2分钟前
tesla完成签到 ,获得积分10
2分钟前
大水完成签到 ,获得积分10
2分钟前
xxiao完成签到 ,获得积分20
2分钟前
3分钟前
丰富的归尘完成签到 ,获得积分10
3分钟前
YA应助小花爱科研采纳,获得10
3分钟前
3分钟前
3分钟前
胖小羊完成签到 ,获得积分10
3分钟前
飞云完成签到 ,获得积分10
3分钟前
3分钟前
Hiram完成签到,获得积分10
3分钟前
DocRex发布了新的文献求助10
3分钟前
4分钟前
DocRex完成签到,获得积分10
4分钟前
spark810发布了新的文献求助10
4分钟前
小花爱科研完成签到 ,获得积分20
4分钟前
叶子完成签到,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
壮壮妞完成签到,获得积分20
4分钟前
壮壮妞发布了新的文献求助10
5分钟前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3229760
求助须知:如何正确求助?哪些是违规求助? 2877260
关于积分的说明 8198668
捐赠科研通 2544727
什么是DOI,文献DOI怎么找? 1374645
科研通“疑难数据库(出版商)”最低求助积分说明 647015
邀请新用户注册赠送积分活动 621836